drugset
drugset / Trial / NCT04938453

A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule

NCT04938453 ↗

Phase 1 Completed 20 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the relative bioavailability of 100 mg nintedanib given as four capsules of 25 mg nintedanib compared with one capsule of 100 mg nintedanib.

Timeline

Start
2021-07-14
Primary completion
2021-08-30
Completion
2021-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule 25 mg Oral
Subject Nintedanib Small molecule 100 mg Oral

Indications

No indication recorded.